Fig. 5From: Avoiding future controversies in the Alzheimer’s disease space through understanding the aducanumab data and FDA reviewNo systematic effect of PV4 in treatment arms that did not have a dose change (Study 301 and 302). Pre- and post-PV4 mean change from baseline in the placebo and low-dose groupsBack to article page